Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Lexicon Pharmaceuticals Inc LXRX

Healthcare Biotechnology
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The Company pipeline includes INPEFA (sotagliflozin), LX9211, and LX9851. Sotagliflozin is an orally delivered small molecule compound that is being developed for the treatment of heart failure... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:LXRX)

New Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA® (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction

GlobeNewswire 3 days ago

Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024

GlobeNewswire 8 days ago

Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire May 2, 2024

Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon Pharmaceuticals

GlobeNewswire April 29, 2024

Lexicon Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 2, 2024

GlobeNewswire April 29, 2024

Lexicon Pharmaceuticals to Host 2024 Investor Day

GlobeNewswire April 18, 2024

Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference

GlobeNewswire April 3, 2024

Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo

GlobeNewswire March 25, 2024

New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease

GlobeNewswire March 12, 2024
View More News ››

Opinion & Analysis (NDAQ:LXRX)

Sanofi Pays Lexicon Pharma $260 Million to Settle Diabetes Drug Dispute

Streetwise Reports September 12, 2019
View More Opinion ››

Bullboard Posts (NDAQ:LXRX)

missed it by that much as

it was a bargain in the summer,another one on my watchlist,but you can't win them al,so glta.
coolfooldumbguy - January 2, 2020

Loss narrows and uptrend is born

LXRX moved above resistance and crossed its 50-day moving average.Next target SPlooks like $3Lexicon Pharmaceuticals Inc. reported fourth...
mart33 - March 24, 2008
View more Bullboard ››

Permex Petroleum Corp

Permex Petroleum Corp

Permex Petroleum Corporation is a junior oil and gas company. The Company is engaged in the acquisition, exploration ...
View More »